Fever News and Research

RSS

HHS awards contracts totaling more than $232 million to fund development of new vaccines against smallpox, plague and tularemia

United States Department of Health and Human Services has announced four new contracts totaling more than $232 million to fund development of new vaccines against three potential agents of bioterrorism: smallpox, plague and tularemia. The National Institute of Allergy and Infectious Diseases (NIAID), will administer the contracts.

8 Oct 2004

Aspirin might well be considered the top utility player in the medicine cabinet

This cheap over-the-counter drug can be used not only for fever, pain and arthritis, but to prevent heart attack, stroke or angina. It also may reduce the risk of colorectal cancer. Yet aspirin also has side effects worth considering, and its very accessibility may hamper its use.

8 Oct 2004

Another enterovirus 71 case confirmed in Hong Kong

The Hong Kong's Centre for Health Protection has confirmed another enterovirus 71 in a 21-month-old boy, bringing this year's total to 34. He travelled to the Mainland from September 3 to 5.

6 Oct 2004

Influenza is a contagious disease caused by an RNA virus of the orthomyxoviridae family

Influenza (or as it is commonly known, the flu) is a contagious disease caused by an RNA virus of the orthomyxoviridae family (The orthomyxoviridae is a family of RNA viruses which infect vertebrate).

6 Oct 2004

Health Protection Agency investigates national outbreak of salmonella

The UK's Health Protection Agency, together with colleagues in the NHS and Local Authorities, has been carrying out an investigation into a national outbreak of Salmonella.

5 Oct 2004

Giving flu vaccine to toddlers in the spring and fall guards against infection

Giving flu vaccine to toddlers in the spring and fall guards against infection and is easier on parents than the fall schedule of two doses administered a month apart, found researchers from Duke University Medical Center and the University of Washington.

4 Oct 2004

Each year, between 25 million and 50 million Americans will suffer with the flu

Each year, between 25 million and 50 million Americans will suffer with the fever, chills, body aches and upper respiratory problems brought on by viral influenza, better known as the flu.

30 Sep 2004

Cutting levels of household allergens is unlikely to have much impact on childhood asthma

Cutting levels of household allergens, such as cat dander and dust mite, is unlikely to have much impact on the subsequent development of childhood asthma and respiratory allergies, suggests research in Thorax.

29 Sep 2004

Women aged 16 to 19 are 43% more likely to test positive for Chlamydia than women in their early twenties

Women aged 16 to 19 are 43% more likely to test positive for Chlamydia than women in their early twenties, show data from the first year of the Chlamydia screening programme in England, reported in Sexually Transmitted Infections.

29 Sep 2004

Chiron CEO to appear before the U.S. Senate Special Committee on Aging

Chiron Corporation announced that president and chief executive officer Howard Pien will appear before the U.S. Senate Special Committee on Aging in Washington, D.C., today in a hearing titled, "Combating the Flu: Keeping Seniors Alive."

28 Sep 2004

Two new cases of leptospirosis confirmed in Hong Kong

Hong Kong's Centre for Health Protection (CHP) of the Department of Health has confirmed two new cases of leptospirosis involving participants of the hiking activity "Team Challenge 36" held in August.

28 Sep 2004

Five new human cases of West Nile virus confirmed in Mississippi

The Mississippi State Department of Health has confirmed five additional human cases of West Nile virus - one in Hinds County, one in Lee County, one in Pike County and two in Rankin County residents.

26 Sep 2004

Ranbaxy receives FDA approval to market Loratadine and Pseudoephedrine Sulfate extended release tablets

Ranbaxy Pharmaceuticals, a wholly-owned subsidiary of Ranbaxy Laboratories Limited of New Delhi, India, announced today that RLL has received approval from the U. S. Food and Drug Administration to manufacture and market Loratadine and Pseudoephedrine Sulfate Extended Release Tablets

26 Sep 2004

Researchers have successfully targeted an HIV protein that has eluded existing therapies

Researchers targeted Nef, a protein responsible for accelerating the development of acquired immunodeficiency syndrome, or AIDS. Nef was targeted with small molecules synthesized by the researchers – molecules that disrupted Nef’s interaction with other proteins.

26 Sep 2004

Lassa Fever, not seen in US for 15 years re-emerges

The New Jersey Department of Health and Senior Services reported today that a 38-year-old Mercer County man died on August 28 from an acute viral disease called Lassa fever, a condition that is rare in the U.S., but endemic to West Africa.

23 Sep 2004

Gene responsible for a rare form of dystonia known as rapid-onset dystonia parkinsonism identified

Investigators funded in part by the National Institute of Neurological Disorders and Stroke (NINDS) have identified the gene responsible for a rare form of dystonia known as rapid-onset dystonia parkinsonism (RDP).

23 Sep 2004

Allow genomic information to be freely available on the internet

This week’s lead editorial in THE LANCET discusses the benefits and potential risks of allowing genomic information to be freely available on the internet

23 Sep 2004

A naturally occurring chemical that may repel yellow fever mosquitoes can now be made in the laboratory

Gaur acid is a natural skin secretion of the gaur, an Asian wild ox. Preliminary evidence suggests that this chemical discourages the landing and feeding of Aedes aegypti, a common mosquito that carries and transmits the yellow fever virus in some parts of the world.

23 Sep 2004

Neck surgeons brush up on West Nile virus

Neck Surgery Foundation Annual Meeting & OTO EXPO, being held September 19-22, 2004, at the Jacob K. Javits Convention Center, New York City, NY.

17 Sep 2004

Wyeth gets approval for needle-less syringe for the treatment of hemophilia

Wyeth Pharmaceuticals has announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the ReFacto Antihemophilic Factor (Recombinant) R2 Kit, the first needle-less reconstitution device with a prefilled diluent syringe for hemophilia.

14 Sep 2004

Fever News and Research

HHS awards contracts totaling more than $232 million to fund development of new vaccines against smallpox, plague and tularemia

Aspirin might well be considered the top utility player in the medicine cabinet

Another enterovirus 71 case confirmed in Hong Kong

Influenza is a contagious disease caused by an RNA virus of the orthomyxoviridae family

Health Protection Agency investigates national outbreak of salmonella

Giving flu vaccine to toddlers in the spring and fall guards against infection

Each year, between 25 million and 50 million Americans will suffer with the flu

Cutting levels of household allergens is unlikely to have much impact on childhood asthma

Women aged 16 to 19 are 43% more likely to test positive for Chlamydia than women in their early twenties

Chiron CEO to appear before the U.S. Senate Special Committee on Aging

Two new cases of leptospirosis confirmed in Hong Kong

Five new human cases of West Nile virus confirmed in Mississippi

Ranbaxy receives FDA approval to market Loratadine and Pseudoephedrine Sulfate extended release tablets

Researchers have successfully targeted an HIV protein that has eluded existing therapies

Lassa Fever, not seen in US for 15 years re-emerges

Gene responsible for a rare form of dystonia known as rapid-onset dystonia parkinsonism identified

Allow genomic information to be freely available on the internet

A naturally occurring chemical that may repel yellow fever mosquitoes can now be made in the laboratory

Neck surgeons brush up on West Nile virus

Wyeth gets approval for needle-less syringe for the treatment of hemophilia

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News